Semaglutide 1mg

Route: Subcutaneous injection, once weekly.

• Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites each week.
• Draw the precise volume yielding 1 mg from the compounded vial; confirm volume with prescriber instructions.
• Administer on the same day each week at any consistent time of day, with or without food.
• Dispose of used needles immediately in an approved sharps container.

Prescriber-directed. Standard context for 1 mg dosing:

• Type 2 diabetes (Ozempic): 1 mg weekly is a maintenance dose after 4+ weeks at 0.5 mg; maximum Ozempic dose is 2 mg weekly.
• Weight management titration: 1 mg is week 9–12 titration step per Wegovy protocol (preceding 1.7 mg and 2.4 mg steps).
• Dose escalation should occur no more rapidly than every 4 weeks to reduce GI side effects.

• Semaglutide: As described for ID 182 and 181; identical pharmacodynamic mechanism. At 1 mg weekly, dose-proportional increases in GLP-1 receptor occupancy and downstream effects (insulin secretion, glucagon suppression, hypothalamic appetite suppression) are observed relative to 0.5 mg. The pharmacokinetic profile (week-long half-life) remains unchanged.

Indication context: Semaglutide 1 mg weekly is the established maintenance dose for type 2 diabetes (Ozempic) that demonstrated approximately 1.5% HbA1c reduction and ~4–6 kg weight loss in the SUSTAIN trial program. It also represents an important step in the weight management titration schedule. Cardiovascular benefit (reduction in MACE) has been demonstrated at this dose in T2DM patients at high CV risk (SUSTAIN-6 trial).

Monitoring: As for semaglutide 0.5 mg—HbA1c, body weight, renal function, GI tolerability, ophthalmologic assessment for retinopathy in at-risk patients.

Same safety profile as semaglutide 0.5 mg. At 1 mg, GI adverse effects (nausea, vomiting, diarrhea) are somewhat more frequent than at 0.5 mg but generally manageable. All contraindications, warnings, and drug interactions are identical to those listed for semaglutide 0.5 mg (ID 182).

Store refrigerated (2–8°C). Do not freeze. Protect from light. Once the vial is first punctured, use within the beyond-use date specified by Genesis Compounding (typically 28 days). Do not shake. Keep out of reach of children.

How does the 1 mg dose differ from the 0.5 mg dose?

Higher GLP-1 receptor occupancy at 1 mg produces greater reductions in HbA1c and body weight compared to 0.5 mg, with a modest increase in GI adverse effects during the period after dose escalation. Most patients tolerate 1 mg weekly once they have been maintained on 0.5 mg for at least 4 weeks.

Why are dose increases spaced 4 weeks apart?

Gradual titration allows GI receptors to accommodate increasing GLP-1R stimulation, significantly reducing nausea, vomiting, and other GI side effects that are most common during rapid dose escalation.

Can I use semaglutide if I have kidney disease?

No specific dose adjustment is required for renal impairment based on FDA labeling. However, GI-related dehydration (from nausea/vomiting/diarrhea) can acutely worsen renal function. Monitor renal function closely if GI side effects are significant.

Is this product FDA-approved?

Ozempic 1 mg (subcutaneous semaglutide) is FDA-approved for type 2 diabetes. This compounded preparation is a patient-specific 503A product from Genesis Compounding and is not FDA-approved as a compounded product.